Despite the overall better therapeutic response in tumors that express PD-L1 either on tumor or immune cells [29, 53], the efficacy of anti-PD-1/PD-L1 inhibitors is not at a satisfactory level, especially in TGCTs. This evidence concerns the gene CD274 and neoplasm.